¼¼°è ÀÌ Ä¡·á ½ÃÀå ±Ô¸ð´Â ÀÇ·áºñ Áõ°¡¿Í °¡Ã³ºÐ ¼Òµæ Áõ°¡·Î ÀÎÇØ 2024-2032³â 6.5% ÀÌ»óÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°æÁ¦ºÐ¼®±¹Àº 2023³â ¸¶Áö¸· ºÐ±â±îÁö 12°³¿ù µ¿¾È ¹Ì±¹ °æÁ¦ÀÇ °¡Ã³ºÐ ¼ÒµæÀÌ 4.2% Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. Áö³ 1³â µ¿¾È 1Àδç ÀÚº» ¼ÒµæÀº 2022³â ¸» 57,386´Þ·¯¿¡¼ 2023³â ¸» 61,084´Þ·¯·Î »ó½ÂÇß½À´Ï´Ù.
ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, ¼ÒºñÀÚµéÀº ÀÌ È®»êÀ» °ü¸®ÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ¸¦ ±â²¨ÀÌ Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÀÇ·á ¼ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼º°ú °¡Ã³ºÐ ¼Òµæ ¼öÁØÀÌ Çâ»óµÇ¾î ±âÁ¸ Ä¡·á¹ý»Ó¸¸ ¾Æ´Ï¶ó Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ´Â Áö¿ª¿¡¼ ƯÈ÷ µÎµå·¯Áý´Ï´Ù.
¼ÒºñÀÚÀÇ ´Ù¾çÇÑ ÃëÇâ¿¡ ºÎÀÀÇÏ´Â µ¿½Ã¿¡ Ä¡·á°¡ ¾ö°ÝÇÑ ±âÁØÀ» ÃæÁ·Çϵµ·Ï º¸ÀåÇϱâ À§ÇÑ ÀνÄÀÇ Áõ°¡¿Í ±ÔÁ¦ ȯ°æÀÇ ÁøÈ´Â ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ Á¾ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© Àü ¼¼°è ÀÌ Ä¡·á »ê¾÷ÀÇ Áö¼ÓÀûÀÎ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
ó¹æ¾à ºÎ¹®Àº 2024³âºÎÅÍ 2032³â±îÁö ³î¶ó¿î CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 󹿾àÀº Á¾Á¾ ³»¼º À̰¡ È¿°úÀûÀ¸·Î ÅðÄ¡ÇÒ ¼ö ÀÖ´Â °·ÂÇÑ Á¦Á¦¸¦ Á¦°øÇÏ¿© Ä¡·á È¿°ú¿¡ ´ëÇÑ ¿ì·Á°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á Àü¹®°¡µéÀÌ ÀÌ·¯ÇÑ ¾à¹°À» Á¡Á¡ ´õ ¸¹ÀÌ Ã³¹æÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ½É°¢ÇÑ °¨¿°À̳ª ½ÃÁß¿¡¼ ÆÇ¸ÅµÇ´Â Ä¡·áÁ¦·Î´Â ÃæºÐÇÏÁö ¾ÊÀº °ÍÀ¸·Î ÀÔÁõµÈ °æ¿ìÀÇ °ü¸®¿¡¼ ÀÌ·¯ÇÑ ¾à¹°ÀÇ ¿ªÇÒÀ» °Á¶Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ó¹æÀü Ä¡·á´Â ´õ ½Å·ÚÇÒ ¼ö ÀÖ´Â °ÍÀ¸·Î Àνĵǰí ÀÖÀ¸¸ç, À̰¡ È®»ê¿¡ ´ëÇÑ º¸´Ù ½Å¼ÓÇϰí Á¾ÇÕÀûÀÎ ÇØ°áÃ¥À» ¿øÇÏ´Â »ç¶÷µéÀÌ ¼±È£Çϰí ÀÖ¾î ÀÌ Àü¹® ºÐ¾ßÀÇ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
2032³â±îÁö ºê·£µå ÀǾàǰÀÌ ÀÌ Ä¡·á ½ÃÀå¿¡¼ Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºê·£µå ÀǾàǰÀº È¿´É°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ¸í¼ºÀÌ È®¸³µÈ °æ¿ì°¡ ¸¹À¸¸ç, ¼ÒºñÀÚÀÇ ½Å·Ú¸¦ ¾ò°í ÀÖ½À´Ï´Ù. ¾à±¹ ¹× ¿Â¶óÀÎ Ç÷§Æû¿¡¼ÀÇ ¸¶ÄÉÆÃ ³ë·Â°ú ÀÎÁöµµ ¶ÇÇÑ ¼ÒºñÀÚÀÇ ÀÎÁöµµ¿Í ¼±È£µµ¸¦ ³ôÀÌ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºê·£µå ÀǾàǰÀº »ç¿ëÇϱ⠽¬¿î ó¹æÀ̳ª ƯÁ¤ ¼ÒºñÀÚ ´ÏÁî¿¡ ºÎÇÕÇÏ´Â ºÎ°¡ ±â´É µî ´Ù¾çÇÑ ÀÌÁ¡À» Á¦°øÇÏ´Â °æ¿ì°¡ ¸¹¾Æ ±× ÀαⰡ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚµéÀÌ ÀÌ °¨¿°À» È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇØ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¼Ö·ç¼Ç°ú Æí¸®ÇÑ ¿É¼ÇÀ» ¿ì¼±½ÃÇÏ¸é¼ ºê·£µå ºÎ¹®Àº °è¼Ó È®´ëµÇ°í ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È À¯·´ÀÇ ÀÌ Ä¡·á ½ÃÀåÀº °ß°íÇÑ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À̵¿°ú ¿©ÇàÀÇ Áõ°¡´Â ÀÌ È®»ê¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Çб³¿Í Á÷ÀåÀÇ ¾ö°ÝÇÑ À§»ý ±âÁØÀº ½Å¼ÓÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯·´ ±¹°¡µéÀÇ ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÏ¸é¼ Ã³¹æ¾à ¹× ÀϹÝÀǾàǰÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº °³ÀÎ À§»ý°ú °Ç°¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ À¯·´¿¡¼ ÀÌ Ä¡·á »ê¾÷ÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
Global Lice Treatment Market will record over 6.5% CAGR from 2024 to 2032, ushered by increased healthcare expenses and rising disposable incomes. The Bureau of Economic Analysis reported a 4.2% growth in disposable income in the U.S. economy for the 12 months ending in the last quarter of 2023. Over the year, per capital income rose from 57,386 at the end of 2022 to 61,084 at the end of 2023.
As healthcare spending amplifies, consumers are more willing to invest in effective solutions for managing lice infestations. This trend is particularly pronounced in regions where access to healthcare services and disposable income levels have improved, fostering demand for traditional as well as innovative treatment alternatives.
Heightened awareness and evolving regulatory landscapes propel the market expansion, ensuring that treatments meet strict standards while catering to diverse consumer preferences. These factors collectively contribute to the sustained growth of the lice treatment industry globally.
The overall lice treatment market is classified based on product type, type, route of administration, condition, dosage form, distribution channel, and region.
The prescription medications segment will register an impressive CAGR between 2024 and 2032. Prescription medications often offer stronger formulations that can effectively eradicate resistant lice strains, addressing growing concerns over treatment efficacy. Additionally, healthcare professionals increasingly prescribe these medications, emphasizing their role in managing severe infestations or cases where over-the-counter remedies have proven inadequate. Moreover, prescription treatments are perceived as more reliable and are preferred by individuals seeking quicker and more comprehensive solutions to lice infestations, boosting demand within this specialized segment of the market.
By 2032, the branded sector will hold a substantial lice treatment market share. Branded treatments often carry established reputations for efficacy and safety, which instill consumer confidence. Their marketing efforts and visibility in pharmacies and online platforms also contribute to increased consumer awareness and preference. Furthermore, branded treatments frequently offer additional benefits. such as user-friendly formulations or added features that appeal to specific consumer needs, further driving their popularity. The branded segment continues to expand as consumers prioritize trusted solutions and convenient options for managing lice infestations effectively.
During the forecast period, the Europe lice treatment market will showcase a robust CAGR. Increased migration and travel contribute to the spread of lice infestations, prompting higher demand for effective treatments. Moreover, stringent hygiene standards in schools and workplaces necessitate quick and reliable solutions, catapulting the market growth. Additionally, rising healthcare expenditures across European countries enable greater access to a variety of treatment options, including both prescription and over-the-counter remedies. These factors, coupled with a growing awareness of personal hygiene and health, propel the expansion of the lice treatment industry in Europe.